Antibody therapies are rapidly transforming the treatment landscape of non-Hodgkin lymphoma (NHL). Since the development of rituximab as an anti-CD20 antibody, there has been an intense research interest in antibody-based therapeutic approaches. The use of antibody-drug conjugates, monoclonal antibodies, and bispecific antibodies are increasingly being investigated in clinical trials for the treatment of NHL, particularly in diffuse large B-cell lymphoma (DLBCL) and in the relapsed/refractory setting, offering alternative strategies for disease management.
In this podcast, Gilles Salles, MD, PhD, of the Memorial Sloan Kettering, New York, NY, Martin Hutchings, MD, PhD, of the Copenhagen University Hospital, Copenhagen, Denmark, Moshe Yair Levy, MD, of the Baylor Charles A. Sammons Cancer Center, Dallas, TX, Paolo Caimi, MD, of the University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, OH, and Nilanjan Ghosh MD, PhD, of the Levine Cancer Institute, Charlotte, NC, discuss the latest clinical updates on the use of antibody therapies for the treatment of NHL, as presented at the European Hematology Association (EHA) Congress 2021 and the International Conference on Malignant Lymphoma (ICML), 2021.
The AML sessions: venetoclax-based regimens
The AML Sessions: IDH inhibitors
The AML sessions: advances in immuno-oncology from SOHO 2020
Advances in CAR-T and cellular therapy from EBMT 2020: MSCs, clinical trial updates and gene-edited effector cells
SOHO 2020: Next questions in hematological malignancies
CLL therapy: the latest trial updates and innovative novel therapies for the future
The MPN Sessions: pathobiology, therapeutic strategies & clinical trials
Latest AML therapies: novel preparations and first in class agents
Advances in the lymphoma space: targeted therapies, PET-guided omission of RT and CAR T-cells
The Myeloma Sessions: Evolving management of myeloma & COVID-19
CLL: MRD and first-in-class agents
MPNs highlights at EHA 2020: clinical trials, novel therapies & pitfalls
The CLL Sessions: frontline therapy, BTK inhibitors, MRD negativity & novel therapies
The HemOnc & COVID-19 Sessions: treating hematological malignancies, reducing nosocomial COVID-19 infections, clinical trial participation and resourc...
The AML Sessions: emerging immunotherapies, venetoclax-based regimens and targeted therapies in AML
Key updates in ALL at EHA 2020
The Myeloma Sessions: smoldering myeloma, MRD evaluation, R/R disease & transplant-eligible patients
Systemic mastocytosis: current landscape, novel agents and COVID-19
MRD assessment in AML: incorporation into clinical practice
Myeloma management in the COVID-19 era
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive